Cardiovascular Risk Factors, Dyslipidemia, Hypertension, Obesity, Overweight, Tobacco Use, Type 2 Diabetes Mellitus
Conditions
Keywords
Cardiovascular prevention, Risk factor control, Medication adherence, Clinical follow-up
Brief summary
This study aims to evaluate cardiovascular risk factors, clinical characteristics, and outcomes in adult patients attending an outpatient cardiology clinic. The research focuses on identifying predictors of adverse cardiovascular events, optimizing risk stratification, and improving preventive strategies in routine clinical practice. Data will be collected from patients receiving standard cardiology care without altering their treatment. The results are expected to contribute to better understanding of cardiovascular risk profiles and to support improvements in clinical decision-making and patient management.
Interventions
OTHERStructured Cardiovascular Risk Management
Protocol-based clinical management including periodic evaluation and adjustment of antihypertensive, lipid-lowering, antidiabetic, and lifestyle interventions according to routine clinical practice guidelines.
Sponsors
Universidad Católica San Antonio de Murcia
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
Participants receive structured clinical follow-up with periodic evaluation and adjustment of standard pharmacological therapy under routine clinical practice using a before-and-after design.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥18 years * Presence of at least one cardiovascular risk factor (hypertension, diabetes, dyslipidemia, obesity, or smoking) * Receiving outpatient clinical follow-up * Ability to provide informed consent
Exclusion criteria
* Severe clinical instability requiring hospitalization * Pregnancy * End-stage renal disease or dialysis * Inability to complete follow-up visits * Refusal to participate
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in systolic blood pressure | Baseline to 90 days | Change in systolic blood pressure (mmHg) measured under standardized conditions to evaluate the effect of structured clinical and pharmacological cardiovascular risk management. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in diastolic blood pressure | Baseline to 90 days | Evaluation of changes in diastolic blood pressure following structured clinical and pharmacological management. |
| Change in LDL cholesterol | Baseline to 90 days | Evaluation of changes in LDL cholesterol measured during routine laboratory assessment after structured cardiovascular risk management. |
| Change in HbA1c | Baseline to 90 days | Evaluation of changes in glycated hemoglobin (HbA1c) following structured cardiovascular risk management. |
| Change in body weight | Baseline to 90 days | Evaluation of changes in body weight following lifestyle counseling and structured cardiovascular risk management. |
| Change in renal function (eGFR) | Baseline to 90 days | Evaluation of changes in renal function assessed by estimated glomerular filtration rate following structured cardiovascular risk management. |
| Change in HDL cholesterol | Baseline to 90 days | Evaluation of changes in HDL cholesterol measured during routine laboratory assessment after structured cardiovascular risk management. |
| Change in triglycerides | Baseline to 90 days | Evaluation of changes in triglyceride levels measured during routine laboratory assessment after structured cardiovascular risk management. |
| Change in total cholesterol | Baseline to 90 days | Evaluation of changes in total cholesterol measured during routine laboratory assessment after structured cardiovascular risk management. |
| Change in fasting plasma glucose | Baseline to 90 days | Evaluation of changes in fasting plasma glucose following structured cardiovascular risk management. |
| Change in body mass index | Baseline to 90 days | Evaluation of changes in body mass index following lifestyle counseling and structured cardiovascular risk management. |
| Change in microalbuminuria | Baseline to 90 days | Evaluation of changes in urinary albumin excretion to assess microalbuminuria during follow-up after structured cardiovascular risk management. |
Countries
Chile
Contacts
CONTACTJulio César Núñez Farías, MD, MSc (Cardiology)
STUDY_CHAIRJosé Abellán Alemán, MD, PhD
Universidad Católica San Antonio de Murcia
Outcome results
None listed